(Q37812011)

23 August 2017

title

Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? (English)

1 reference

23 August 2017

0 references

1 reference

2

Doruk Erkan

1 reference

23 August 2017

Medha Barbhaiya

1

1 reference

23 August 2017

publication date

1 February 2011

1 reference

Current Rheumatology Reports

23 August 2017

published in

1 reference

23 August 2017

volume

13

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

59-69

1 reference

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11926-010-0149-3

Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-010-0149-3

Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-010-0149-3

New targeted therapies for treatment of thrombosis in antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-010-0149-3

Risk of thromboembolism in patients with idiopathic autoimmune hemolytic disease and antiphospholipid antibodies: results from a prospective, case-control study

21 January 2018

1 reference

12 December 2020

Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty

1 reference

12 December 2020

Autoimmune hemolytic anemia in patients with systemic lupus erythematosus

1 reference

12 December 2020

Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients

1 reference

12 December 2020

Clinical consequences of antiphospholipid antibodies: an historic cohort study

1 reference

12 December 2020

Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups

1 reference

12 December 2020

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

1 reference

12 December 2020

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

1 reference

12 December 2020

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

12 December 2020

Antiphospholipid syndrome in systemic lupus erythematosus: is the whole greater than the sum of its parts?

1 reference

12 December 2020

Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study

1 reference

12 December 2020

Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals

1 reference

12 December 2020

Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment

1 reference

12 December 2020

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry

1 reference

12 December 2020

Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus

1 reference

12 December 2020

Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples

1 reference

12 December 2020

Antiphospholipid antibodies in adults with immune thrombocytopenic purpura

1 reference

12 December 2020

The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome

1 reference

12 December 2020

Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells

1 reference

12 December 2020

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

1 reference

12 December 2020

Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis

1 reference

12 December 2020

Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism

1 reference

12 December 2020

An Update on Aspirin in the Primary Prevention of Cardiovascular Disease

1 reference

12 December 2020

Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model

1 reference

12 December 2020

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

1 reference

12 December 2020

Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients

1 reference

12 December 2020

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

1 reference

12 December 2020

Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events

1 reference

12 December 2020

Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients

1 reference

12 December 2020

Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases

1 reference

12 December 2020

Clinical course of high-risk patients diagnosed with antiphospholipid syndrome

1 reference

12 December 2020

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome

1 reference

12 December 2020

Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort

1 reference

12 December 2020

Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura

1 reference

12 December 2020

Risk factors associated with thrombosis in patients with antiphospholipid antibodies.

1 reference

12 December 2020

Guidelines on cardiovascular disease prevention in clinical practice: the European perspective

1 reference

12 December 2020

Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?

1 reference

12 December 2020

Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype

1 reference

12 December 2020

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.

1 reference

12 December 2020

1 reference

12 December 2020

Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome

1 reference

12 December 2020

Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

1 reference

12 December 2020

High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin

1 reference

12 December 2020

Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor

1 reference

12 December 2020

The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies

1 reference

12 December 2020

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events.

1 reference

12 December 2020

The lady aspirin for cardiovascular disease

1 reference

12 December 2020

New approaches for managing antiphospholipid syndrome

1 reference

12 December 2020

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

1 reference

12 December 2020

A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis

1 reference

12 December 2020

Recurrent miscarriage and long-term thrombosis risk: a case-control study.

1 reference

12 December 2020

Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis

1 reference

12 December 2020

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

1 reference

12 December 2020

Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study

1 reference

12 December 2020

Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects

1 reference

12 December 2020

Assessment of the 2006 revised antiphospholipid syndrome classification criteria

1 reference

12 December 2020

Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome

1 reference

12 December 2020

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals

1 reference

12 December 2020

Aspirin for primary prevention of cardiovascular events in people with diabetes

1 reference

12 December 2020

Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial

1 reference

12 December 2020

The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus.

1 reference

12 December 2020

Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis

1 reference

12 December 2020

Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort

1 reference

12 December 2020

Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients

1 reference

12 December 2020

Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?

1 reference

12 December 2020

Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers

1 reference

12 December 2020

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

1 reference

12 December 2020

Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations.

1 reference

12 December 2020

10.1007/S11926-010-0149-3

Identifiers

DOI

1 reference

23 August 2017

1 reference